Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, May 2, 2012

May Begins With Hepatitis C Disease Management, Drugs and Research

Greetings,

The "Digital Liver Disease Journal" is an official digital educational resource from the American Association for the Study of Liver Diseases.

The journals first issue was launched in February 2012 offering continuing medical education-CME, with video-abstracts, full data, and file downloads in either HTML or PDF formats. View the first issue here, and the new April issue  here.

The full text articles in the second volume-published online a few days ago can only be accessed through payment, however, all corresponding video abstracts and author interviews from the 2011 AASLD meeting remain open access.

Topic Highlights
Issues in selecting HCV-infected candidates for anti-viral treatment (pages 29–31)
Abstract
Watch the interview with the authors

Is there still a role for liver biopsy in managing hepatitis C virus infections? (pages 32–35)
Abstract
Watch the interview with the authors
Watch the video presentation of this article

Managing drug-drug interactions with boceprevir and telaprevir (pages 36–40)
Abstract
Watch the interview with the authors
Watch the video presentation of this article

Importance of patient education and monitoring among HCV-infected patients selected for anti-viral treatment (pages 41–45)
Abstract
Watch the interview with the authors

Predicting the response to the treatment of hepatitis C virus infection (pages 46–48)
Abstract
Watch the interview with the authors
Watch the video presentation of this article

Treatment options for anti-HCV treatment-experienced patients (pages 49–50)
Abstract
Watch the interview with the authors

Management of adverse events during the treatment of chronic hepatitis C infection (pages 54–57)
Abstract
Watch the interview with the authors
Watch the video presentation of this article

Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection (pages 58–61)
Abstract
Watch the interview with the authors

Reminder-
If you missed the link yesterday to the "2012 EASL Internet Symposium" at Viral Ed, you may be interested in the CME discussing key studies in HCV management and treatment.

Whats New At HCV Advocate ?

1. May 2012 Newsletter
In This Issue:

HCV-Related Deaths and Cost-Effectiveness of Testing and Treatment by Alan Franciscus, Editor-in-Chief – Read about three important studies that examined the cost-effectiveness of testing the baby boomer population, treating them with current HCV medications and the future diease progression of the HCV population.

What You Don't Know, You Can Sell by Tracy Swan, TAG — An editorial by Tracy Swan from Treatment Action Group about the conscious decision by Merck to wait before conducting drug-drug interaction studies with boceprevir that put people at risk.

HCV Snapshots by Lucinda K. Porter, RN—In this month's column, Lucinda discusses the use of PEG/RBV for liver cancer, the liver and the brain and much more.

IN MEMORIAM: Michael Carden 1971-2012
—Alan Franciscus, Editor-in-Chief

HealthWise: May is Hepatitis Awareness Month by Lucinda K. Porter, RN—In this month's HealthWise column, Lucinda writes about awareness and the first ever national HCV testing day.

Boceprevir and Telaprevir Improve Cure Rates for HIV/HCV Coinfected People by Liz Highleyman—Liz writes about some of the information presented at this year's EASL conference, in particular about the treatment of HCV with boceprevir and telaprevir in people who are coinfected with HIV and HCV. 

2. Blog: EASL 2012 —Read about the important news about studies on HCV treatment that were presented at EASL.

3. May 2012 HBV Journal Review by Christine M. Kukka—Stay updated on the latest HBV information. Below is just a small sample of the articles summarized in this month’s review:

Hepatitis B plus a Family History of Liver Cancer Increases Cancer Risk 70-Fold

Researchers Suggest Tears and Saliva May Transmit HBV Infection

REVEAL Study Shows Links between HBV DNA and Liver/Pancreatic Cancers

Telbivudine Cuts Mother-to-Infant Hepatitis B Transmission to Zero
and more....................

New From Hep C Challenge
View 2012-2011 Monthly Literature Reviews
At CAP Hepatitis C Literature Review

May 2012 Abstracts

No comments:

Post a Comment